Evidence map›Paper›PMID 37736100›Full record

Trial reportFrontiers in immunology2023

Study of efficacy and antibody duration to fourth-dose booster of Ad5-nCoV or inactivated SARS-CoV-2 vaccine in Chinese adults: a prospective cohort study.

Nani Xu, Yu Xu, Rongrong Dai, Lin Zheng, Pan Qin, Peng Wan, Yejing Yang, Jianmin Jiang, Hangjie Zhang, Xiaowei Hu and 1 more

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Nani XuDepartment of Immunization Program, Xihu District Center for Disease Control and Prevention, Hangzhou, China.
Yu XuDepartment of Vaccine, Clinical Trials, CanSino Biologics, Tianjin, China.
Rongrong DaiSchool of Public Health, Hangzhou Medical College, Hangzhou, China.
Lin ZhengDepartment of Immunization Program, Xihu District Center for Disease Control and Prevention, Hangzhou, China.
Pan QinDepartment of Immunization Program, Xihu District Center for Disease Control and Prevention, Hangzhou, China.
Peng WanDepartment of Vaccine, Clinical Trials, CanSino Biologics, Tianjin, China.
Yejing YangDepartment of Immunization Program, Xihu District Center for Disease Control and Prevention, Hangzhou, China.
Jianmin JiangDepartment of Immunization Program, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
Hangjie ZhangDepartment of Immunization Program, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
Xiaowei HuDepartment of Immunization Program, Xihu District Center for Disease Control and Prevention, Hangzhou, China.
Huakun LvDepartment of Immunization Program, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
Hangzhou Center for Disease Control and Prevention · CNZhejiang Center for Disease Control and Prevention · CNCanSino (China) · CNHangzhou Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: China experienced a record surge of coronavirus disease 2019 cases in December 2022, during the pandemic. Methods: We conducted a randomized, parallel-controlled prospective cohort study to evaluate efficacy and antibody duration after a fourth-dose booster with Ad5-nCoV or inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine. Results: A total of 191 participants aged ≥18 years who had completed a three-dose regimen of the inactivated SARS-CoV-2 vaccine 6 months earlier were recruited to receive the intramuscular Ad5-nCoV booster or the inactivated SARS-CoV-2 vaccine. The Ad5-nCoV group had significantly higher antibody levels compared with the inactivated vaccine group at 6 months after the fourth vaccination dose. After the pandemic, the breakthrough infection rate for the Ad5-nCoV and the inactivated vaccine groups was 77.89% and 78.13%, respectively. Survival curve analysis ( Discussion: Compared with a homologous fourth dose, a heterologous fourth dose of Ad5-nCoV elicited a higher immunogenic response in healthy adults who had been immunized with three doses of inactivated vaccine. Nevertheless, the efficacy of the two vaccine types was equivalent after the pandemic.

Indexed as

Breakthrough InfectionsCOVID-19COVID-19 VaccinesAdolescentAdultAntibodiesAntibodies, ViralChinaDisease OutbreaksEast Asian PeopleHumansImmunization, SecondaryPandemicsProspective StudiesSARS-CoV-2Vaccine EfficacyAd5-nCoV vaccineAntibodiesAntibodies, ViralCOVID-19 VaccinesVaccines, InactivatedAd5-nCoVbreakthrough infectionCOVID-19fourth doseSARS-CoV-2

Identifiers

PMID37736100
PMCPMC10510200
OpenAlexW4386476254

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.